Incyte Corporation (LON:0J9P)
London · Delayed Price · Currency is GBP · Price in USD 74.41
-1.70 (-2.23%)
At close: Aug 1, 2025
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
$1,278,788
Profits / Employee
$242,892
Market Cap
11.14B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| HUTCHMED (China) | 1,811 |
| Oxford Nanopore Technologies | 1,382 |
Incyte News
- 3 days ago - Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil - GlobeNewsWire
- 5 days ago - Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Incyte Corporation 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 days ago - Incyte rises on results beat, lifted Jakafi guidance - Seeking Alpha
- 5 days ago - Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
- 5 days ago - Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Benzinga
- 5 days ago - Incyte lifts annual sales forecast for blood cancer drug after solid quarter - Reuters
- 5 days ago - Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Business Wire